CapyBio develops tools and services for precise human cell engineering, helping researchers understand cell identity and guide cells toward desired states. Its work supports research, pre-clinical testing, cell therapy, regenerative medicine, and related applications. The company describes its platform as a navigation system for cell engineering, combining measurement, prediction, and laboratory testing in a continuous feedback loop.

Capybara measures engineered cells by comparing them with primary human references. CellOracle predicts transcription factor perturbations that may move cells toward a target cell fate. Researchers can apply those predictions in the wet lab, then assess the refined cells with Capybara and repeat the process. Single-cell RNA sequencing data is available as an add-on.

CapyBio’s platform draws on peer-reviewed methods for measuring cell identity and predicting cell-fate transitions, with publications in journals including Nature and Cell Stem Cell. The company invites teams to discuss projects and offers access to information about its technology, services, products, and research.